Modern Pathology最新文献

{"title":"Genomic and Transcriptomic Analysis of Ameloblastoma Reveals Distinct Molecularly Aggressive Phenotypes.","authors":"Constanza Marín-Márquez, Akinyele O Adisa, Sven E Niklander, Janine Kirby, Keith D Hunter","doi":"10.1016/j.modpat.2024.100682","DOIUrl":"10.1016/j.modpat.2024.100682","url":null,"abstract":"<p><p>Ameloblastoma (AM) is a benign but locally infiltrative epithelial odontogenic neoplasm of the jawbones that may reach grotesque proportions and be highly recurrent if inadequately removed. The BRAF^V600E mutation has been demonstrated as a key molecular event in its development; nevertheless, there are many queries about its etiopathogenesis, which are yet to be answered. In this study, we aimed to integrate the results from whole-exome sequencing (WES) and RNA sequencing in AM samples to identify novel candidate genes that may be relevant to its pathogenesis. Thirteen-matched tumors were subjected to WES and RNA-seq, respectively, to detect gene mutations and gene expression profiles, along with the presence of gene fusions. Mutations were validated using Sanger sequencing, whereas transcriptome results were validated using qPCR. The results from both molecular techniques were merged in order to identify novel candidate genes that were biologically validated with immunohistochemistry. BRAF^V600E mutation was present in 62% of the analyzed cases, and each AM presented at least 2 or 3 mutations affecting cancer-driver genes. RNA-seq showed different molecular subgroups associated with an aggressive and cancer-related phenotype (epithelial-mesenchymal transition and KRAS gene sets). No gene fusions were detected among the cases. CDH11 and TGM2, novel genes associated with epithelial-mesenchymal transition in AM, were selected and validated in tissues. Both WES and RNA-seq results showed gene alterations related to proliferation, cell differentiation, and metabolic processes. These results show that AM shares many of the hallmarks of cancer secondary to the presence of oncogenic mutations or activation of oncogenic signaling pathways.</p>","PeriodicalId":18706,"journal":{"name":"Modern Pathology","volume":" ","pages":"100682"},"PeriodicalIF":7.1,"publicationDate":"2024-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142829414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Spatially Resolved Single-Cell Transcriptome Analysis of Mycosis Fungoides Reveals Distinct Biomarkers GNLY and FYB1 Compared With Psoriasis and Chronic Spongiotic Dermatitis.","authors":"Joon Min Jung, Chong Hyun Won, Sung Eun Chang, Mi Woo Lee, Woo Jin Lee","doi":"10.1016/j.modpat.2024.100681","DOIUrl":"10.1016/j.modpat.2024.100681","url":null,"abstract":"<p><p>Early mycosis fungoides (MF) and inflammatory dermatoses including psoriasis and chronic spongiotic dermatitis are often difficult to differentiate. We explored diagnostic markers differentiating MF from psoriasis and chronic spongiotic dermatitis via spatially resolved single-cell transcriptome analysis. Single-cell transcriptomics of intraepidermal T cells of MF patches, psoriasis, and chronic spongiotic dermatitis were analyzed using CosMx spatial molecular imager utilizing surface markers, including CD3 and CD4. An immunohistochemical study with potential markers was performed to verify clinical utility. Compared with psoriasis and chronic spongiotic dermatitis, 41 upregulated differentially expressed genes (DEGs) in MF were associated with the T-cell receptor (TCR) signaling pathway and apoptosis regulation. Protein-protein interaction network analysis of these DEGs revealed a main cluster associated with TCR signaling. Pathway enrichment analysis showed that apoptosis, Th17 cell differentiation, and TCR signaling pathways were enriched in MF. GNLY and FYB1, DEGs with the highest fold-change values, were selected as potential diagnostic biomarkers for MF. For immunohistochemistry, biopsy specimens from 150 patients diagnosed with patch MF with CD4⁺ immunophenotype (n = 56), psoriasis (n = 48), and chronic eczema (n = 46) were included. The sensitivity and specificity of granulysin (GNLY) for distinguishing MF and psoriasis/chronic spongiotic dermatitis were 67.9% and 93.6%, respectively. For FYN-binding protein 1 (FYB1), those values were 73.2% and 69.2%, respectively. The area under the receiver operating characteristic curve values of GNLY and FYB1 were 0.86 and 0.79, respectively. In conclusion, granulysin and FYB1 can be promising diagnostic biomarkers for differentiating early-stage MF from psoriasis and chronic spongiotic dermatitis.</p>","PeriodicalId":18706,"journal":{"name":"Modern Pathology","volume":" ","pages":"100681"},"PeriodicalIF":7.1,"publicationDate":"2024-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142829416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic and Prognostic/Therapeutic Significance of Comprehensive Analysis of Bone and Soft Tissue Tumors Using Optical Genome Mapping and Next-generation Sequencing.","authors":"Jen Ghabrial, Victoria Stinnett, Efrain Ribeiro, Melanie Klausner, Laura Morsberger, Patty Long, William Middlezong, Rena Xian, Christopher Gocke, Ming-Tseh Lin, Lisa Rooper, Ezra Baraban, Pedram Argani, Aparna Pallavajjala, Jaclyn B Murry, John M Gross, Ying S Zou","doi":"10.1016/j.modpat.2024.100684","DOIUrl":"https://doi.org/10.1016/j.modpat.2024.100684","url":null,"abstract":"<p><p>Detecting somatic structural variants (SVs), copy number variants (CNVs), and mutations in bone and soft tissue tumors is essential for accurately diagnosing, treating, and prognosticating outcomes. Optical genome mapping (OGM) holds promise to yield useful data on SVs and CNVs but requires fresh or snap-frozen tissue. This study aimed to evaluate the clinical utility of data from OGM compared to current standard-of-care cytogenetic testing. We evaluated 60 consecutive specimens from bone and soft tissue tumors using OGM and karyotyping, FISH, gene fusion assays, and deep next-generation sequencing (NGS). OGM accurately identified diagnostic SVs/CNVs previously detected by karyotyping and FISH (specificity=100%). OGM identified diagnostic and pathogenic SVs/CNVs (∼23% of cases) undetected by karyotyping (cryptic/submicroscopic). OGM allowed detection and further characterization of complex structural rearrangements including chromoanagenesis (27% of cases) and complex 3-6-way translocations (15% of cases). In addition to identifying 321 SVs and CNVs among cases with chromoanagenesis events, OGM identified approximately 9 SVs and 12 CNVs per sample. A combination of OGM and deep NGS data identified diagnostic and pathogenic SVs, CNVs, and mutations in ∼98% of cases. Our cohort contained the most extensive collection of bone and soft tissue tumors profiled by OGM. OGM had excellent concordance with standard-of-care cytogenetic testing, detecting and assigning high-resolution genome-wide genomic abnormalities with higher sensitivity than routine testing. This is the first and largest study to provide insights into the clinical utility of combined OGM and deep sequencing for the pathologic diagnosis and potential prognostication of bone and soft tissue tumors in routine clinical practice.</p>","PeriodicalId":18706,"journal":{"name":"Modern Pathology","volume":" ","pages":"100684"},"PeriodicalIF":7.1,"publicationDate":"2024-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142829412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Non-Generative Artificial Intelligence (AI) in Medicine: Advancements and Applications in Supervised and Unsupervised Machine Learning.","authors":"Liron Pantanowitz, Thomas Pearce, Ibrahim Abukhiran, Matthew Hanna, Sarah Wheeler, T Rinda Soong, Ahmad P Tafti, Joshua Pantanowitz, Ming Y Lu, Faisal Mahmood, Qiangqiang Gu, Hooman H Rashidi","doi":"10.1016/j.modpat.2024.100680","DOIUrl":"https://doi.org/10.1016/j.modpat.2024.100680","url":null,"abstract":"<p><p>The use of Artificial Intelligence (AI) within pathology and healthcare has advanced extensively. We have accordingly witnessed increased adoption of various AI tools which are transforming our approach to clinical decision support, personalized medicine, predictive analytics, automation, and discovery. The familiar and more reliable AI tools that have been incorporated within healthcare thus far fall mostly under the non-generative AI domain, which includes supervised and unsupervised machine learning (ML) techniques. This review article explores how such non-generative AI methods, rooted in traditional rules-based systems, enhance diagnostic accuracy, efficiency, and consistency within medicine. Key concepts and the application of supervised learning models (i.e. classification and regression) such as decision trees, support vector machines, linear and logistic regression, K-nearest neighbor, and neural networks are explained along with the newer landscape of neural network-based non-generative foundation models. Unsupervised learning techniques including clustering, dimensionality reduction, and anomaly detection are also discussed for their role in uncovering novel disease subtypes or identifying outliers. Technical details related to the application of non-generative AI algorithms for analyzing whole slide images is also highlighted. The performance, explainability and reliability of non-generative AI models essential for clinical decision-making is also reviewed, as well as challenges related to data quality, model interpretability, and risk of data drift. An understanding of which AI-ML models to employ and which shortcomings need to be addressed is imperative to safely and efficiently leverage, integrate, and monitor these traditional AI tools in clinical practice and research.</p>","PeriodicalId":18706,"journal":{"name":"Modern Pathology","volume":" ","pages":"100680"},"PeriodicalIF":7.1,"publicationDate":"2024-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142829415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characterizing Nodal Gamma-Delta T-Cell Lymphoma: Clinicopathological and Molecular Insights.","authors":"Ming Liang Oon, Jing Quan Lim, Jan Bosch-Schips, Fina Climent, Rex K H Au-Yeung, Bailey Hutchison, Aliyah R Sohani, Ozgur Can Eren, Jyoti Kumar, Ahmet Dogan, Choon-Kiat Ong, Leticia Quintanilla-Martinez, Siok-Bian Ng","doi":"10.1016/j.modpat.2024.100685","DOIUrl":"https://doi.org/10.1016/j.modpat.2024.100685","url":null,"abstract":"<p><p>Peripheral T-cell lymphomas with gamma-delta phenotype (GDTCL) are rare lymphoid malignancies. Beyond the well-recognized entities of extranodal lymphomas with gamma-delta phenotype as defined by the 5th edition of the WHO Classification of Hematolymphoid Tumors and 2022 International Consensus Classification, there is a group of poorly-defined gamma-delta T-cell lymphomas with predominantly nodal presentation, termed as nodal GDTCL (nGDTCL). In this study, we present a series of 12 cases of EBV-negative nGDTCL, highlighting the clinical, histopathological and molecular features of this rare entity. Seven cases reported in the literature were included for the analysis. Of the 12 cases, nGDTCL shows an increased incidence in elderly males with a median age of 65.5 years. All cases presented primarily with enlarged lymph nodes and 4 cases (4/12; 33.3%) showed involvement of extranodal sites, including skin, liver, spleen and bone marrow. Histologically, 9 cases showed a diffuse and monomorphic proliferation of mostly medium to large lymphoid cells while 3 cases demonstrated a lymphoepithelioid morphology. All cases (12/12, 100%) were positive for CD3 and TCRγδ. CD4, CD8 and CD56 were positive in 66.7% (8/12), 25% (3/12) and 8.3% (1/11) of cases, respectively. Most cases (8/12, 66.7%) showed a non-cytotoxic phenotype. Using immunohistochemistry, the majority of cases (6/8, 75.0%) belonged to the PTCL-GATA3 subtype with GATA3 and/or CCR4 expression and a non-cytotoxic CD4-positive phenotype. Two cases (2/8, 25%) belonged to the PTCL-TBX21 subtype, of which 1 displayed a cytotoxic CD8-positive phenotype. Next-generation sequencing was performed on 9 cases and TP53 mutation was detected in 66.7% (6/9) of cases. Mutations of ATM and KSR2 were identified in 2 cases each. It remains uncertain if nGDTCL represents a distinct entity, and further studies are needed for better characterization. Nonetheless, nodal-based GDTCL should be distinguished from secondary nodal involvement by other extranodal GDTCL and EBV-positive T/NK-cell lymphoproliferative diseases.</p>","PeriodicalId":18706,"journal":{"name":"Modern Pathology","volume":" ","pages":"100685"},"PeriodicalIF":7.1,"publicationDate":"2024-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142829389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Frequency and consequences of immune checkpoint inhibitor-associated inflammatory changes in different organs: an autopsy study over 13-years.","authors":"Umberto Maccio, Andreas Wicki, Frank Ruschitzka, Felix Beuschlein, Sibylle Wolleb, Zsuzsanna Varga, Holger Moch","doi":"10.1016/j.modpat.2024.100683","DOIUrl":"https://doi.org/10.1016/j.modpat.2024.100683","url":null,"abstract":"<p><p>While immune checkpoint inhibitors (ICIs) have revolutionized modern oncology, they are also associated with immune-related adverse events (irAEs). Previous histopathological descriptions of organ-related inflammatory changes do not consider systemic effects of ICIs, because of an absence of comprehensive autopsy studies. We performed a retrospective study on 42 whole-body autopsies of patients treated with ICIs from January 2011 to March 2024 to determine frequency, organ distribution and morphology of ICIs-associated inflammatory changes as well as their clinical relevance. Twenty-three of 42 patients (54.8%) presented irAEs with inflammatory changes in at least one organ. Most frequent irAEs were ICIs-related hypophysitis (N=12, 28.6%), myocarditis (N=8, 19.0%), pneumonitis (N=5, 11.9%), hepatitis (N=6, 14.3%), and adrenalitis (N=5, 11.9%). ICIs-related inflammation was mainly characterized by lympho-histiocytic and macrophage-rich tissue infiltrates, whereas a granulomatous \"sarcoid-like\" reaction was observed in one patient. Cause of death was attributable to ICIs-therapy in 7 patients (16.7%), with ICIs-associated myocarditis as the most common cause of death (N=5, 71.4%). Clinically, irAEs were unsuspected in 5 of 7 ICIs-related deaths (71.4%). Among irAEs, myocarditis has been clinically undiagnosed in 5 out of 8 cases (62.5%). Encephalitis was identified only at autopsy in all cases (N=2). Hypophysitis was clinically unsuspected in 8 of 12 cases (66.7%). Patients who died from irAEs developed more frequently a complete tumor regression than patients who died from other causes (P=0.018). Of note, ICIs-related myocarditis and pneumonitis were both associated with a systemic occurrence irAEs. Our study demonstrates that some irAEs, especially myocarditis, hypophysitis, and encephalitis are clinically underdiagnosed. Autopsy remains a valuable tool to monitor diagnostic accuracy and therapeutic side effects in patients who died under ICIs-therapy.</p>","PeriodicalId":18706,"journal":{"name":"Modern Pathology","volume":" ","pages":"100683"},"PeriodicalIF":7.1,"publicationDate":"2024-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142829413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"OTP, CD44, and Ki-67: A Prognostic Marker Panel for Relapse-Free Survival in Patients with Surgically Resected Pulmonary Carcinoid.","authors":"Laura Moonen, Jules L Derks, Michael A den Bakker, Lisa M Hillen, Robert Jan van Suylen, Jan H von der Thüsen, Lisa M V Lap, Britney J C A Marijnissen, Ronald A Damhuis, Kim M Smits, Esther C van den Broek, Wieneke A Buikhuisen, Anne-Marie C Dingemans, Ernst Jan M Speel","doi":"10.1016/j.modpat.2024.100677","DOIUrl":"10.1016/j.modpat.2024.100677","url":null,"abstract":"<p><p>Although most patients with pulmonary carcinoid (PC) can be cured by surgery, relapse may occur until 15 years after resection in up to 10% of patients. This is unpredictable at the outset, necessitating extensive follow-up (FU). We sought to determine whether an immunohistochemical marker panel (OTP, CD44, and Ki-67) could better indicate relapse-free survival (RFS) and increase uniformity among pathologists regarding carcinoid classification. To this purpose, all surgically resected PC (2003-2012) were identified in the Dutch cancer/pathology registry, and a matched relapse vs nonrelapse cohort (ratio 1:2, N = 161) was created. Cases were revised by 4 pathologists and additionally for immunohistochemistry (IHC) markers. The marker panel was applied to the complete population-based cohort (N = 536) to investigate the negative predictive value (NPV) of relapse. Median FU was 86.7 months. WHO classification among pathologists revealed poor overall agreement (mitotic count: 0.380, necrosis: 0.476) compared with IHC markers (Ki-67: 0.917, OTP: 0.984, CD44: 0.976). The mean NPV of all pathologists increased from 0.74 (World Health Organization, WHO) to 0.85 (IHC marker panel). IHC risk stratification of the complete cohort, regardless of subtype, showed a statistically significant difference in RFS between patients with high risk (n = 222) and low risk (n = 314), with an NPV of 95.9%. In conclusion, our results support the use of biomarker-driven FU management for patients with PC as the OTP/CD44/KI-67 marker panel can reliably predict which patients will probably not develop relapse over time and may benefit from a more limited postoperative follow-up. Furthermore, IHC marker assessment by pathologists for PC stratification is superior to traditional WHO typing.</p>","PeriodicalId":18706,"journal":{"name":"Modern Pathology","volume":" ","pages":"100677"},"PeriodicalIF":7.1,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142780554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Location of Fibroblastic Foci: Does the Lesion You Observe Really Suggest Usual Interstitial Pneumonia?","authors":"Hiroyuki Katsuragawa, Hiroaki Ito, Tomohiro Handa, Masatsugu Hamaji, Toshi Menju, Ryo Sakamoto, Hiroshi Date, Hironori Haga, Akihiko Yoshizawa","doi":"10.1016/j.modpat.2024.100675","DOIUrl":"10.1016/j.modpat.2024.100675","url":null,"abstract":"<p><p>Fibroblastic foci (FF) are considered important findings of usual interstitial pneumonia (UIP); however, they are not only specific to UIP but also observed in various fibrotic interstitial lung diseases (ILDs). Previous studies have reported the significance of FF comparing UIP with nonspecific interstitial pneumonia (NSIP) or secondary interstitial pneumonia, such as collagen vascular disease-related ILD (CVD-ILD) or fibrotic hypersensitivity pneumonitis (FHP). However, only few studies have mentioned their location, and no reports have shown significant results regarding their location. This study aimed to compare the spatial distribution of FF across various forms of ILDs, based on anatomical location. Among patients who underwent lung transplantation at Kyoto University Hospital between April 1, 2008, and March 31, 2023, those diagnosed with idiopathic pulmonary fibrosis (IPF) (n = 24), idiopathic NSIP (n = 11), CVD-ILD (n = 36), and FHP (n = 12) were included, and 744 slides were obtained. FF were classified into 4 categories: peripheral, such as subpleural/paraseptal; intralobular, along the alveolar wall (aFF); centrilobular (cFF); and distorted or dense fibrotic lesions. The number of total and each location's FF/cm² were counted, and the percentage of each location's FF was calculated. IPF showed more total FF and peripheral FF than NSIP. FHP had more cFF than CVD (P = .026) and NSIP (P = .018). The dFF was higher in IPF than that in CVD (P = .018) and NSIP (P = .039). The aFF/total FF ratio was higher in CVD than that in FHP (P = .021) and IPF (P < .001). A high cFF/total FF ratio was correlated with FHP versus IPF (P = .032). In conclusion, FF with existing peripheral and distorted/dense fibrosis were more closely related to IPF, whereas cFF were highly correlated with FHP. Moreover, a high aFF/total FF ratio was suggestive of CVD.</p>","PeriodicalId":18706,"journal":{"name":"Modern Pathology","volume":" ","pages":"100675"},"PeriodicalIF":7.1,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142770358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"POLE-Mutated Uterine Carcinosarcomas: A Clinicopathologic and Molecular Study of 11 Cases.","authors":"Phoebe M Hammer, Amir Momeni-Boroujeni, David L Kolin, Leandra Kingsley, Ann Folkins, Rachel L P Geisick, Chandler Ho, Carlos J Suarez, Brooke E Howitt","doi":"10.1016/j.modpat.2024.100676","DOIUrl":"10.1016/j.modpat.2024.100676","url":null,"abstract":"<p><p>Uterine carcinosarcomas (UCS) are high-grade biphasic neoplasms with generally poor outcomes. Based on The Cancer Genome Atlas molecular classification of endometrial carcinomas, the majority of UCS are classified as copy-number high/serous-like (p53-abnormal); however, a small subset represent other molecular subtypes, including those that harbor POLE mutations. We identified 11 POLE-mutated (POLEmut) UCS across 3 institutions and assessed the clinical, histopathologic, immunohistochemical, and molecular features of these tumors. POLEmut UCS occurred in adult women (median age, 64 years; range, 48-79 years) and usually presented as The International Federation of Gynecology and Obstetrics 2009 clinical stage IA (n = 4) or IB (n = 3). Almost all tumors were predominantly carcinomatous (n = 10), with most showing endometrioid morphology (n = 7), followed by ambiguous (n = 4) and serous (n = 3) histotypes. By immunohistochemistry, 7 tumors showed aberrant or subclonally aberrant expression of p53, 6 of which harbored pathogenic mutations in TP53 by sequencing. Other frequent mutations included PIK3CA (10/11), PTEN (8/11), RB1 (7/11), ARID1A (7/11), ATM (6/11), PIK3RA (5/11), and FBXW7 (4/11). Two tumors demonstrated loss of mismatch repair protein expression, and 1 had subclonal loss. Heterologous differentiation was uncommon, and only chondrosarcomatous type (n = 2) was observed. Mean and median follow-ups were 24.3 and 14.1 months, respectively (range, 1.4-61.1 months). Ten patients (91%) had no recurrences or death from disease, although 3 of these had follow-up periods <1 year. One patient, with the subclonal POLE variant, presented with stage IV disease and died 1.4 months after surgery. In conclusion, POLEmut UCS demonstrate unique morphologic and immunohistochemical features compared with their p53-abnormal counterparts and may have significant prognostic differences. Our study supports full molecular classification of UCS. We also raise awareness for potentially assessing POLE mutation allele frequency and clonality in consideration of classifying a tumor as POLEmut.</p>","PeriodicalId":18706,"journal":{"name":"Modern Pathology","volume":" ","pages":"100676"},"PeriodicalIF":7.1,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142770365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of ASCL1/NEUROD1/POU2F3/YAP1 Yields Novel Insights for the Diagnosis of Olfactory Neuroblastoma and Identifies Sinonasal Tuft Cell-Like Carcinoma.","authors":"Christopher A Febres-Aldana, Mahmoud M Elsayad, Maelle Saliba, Umesh Bhanot, Peter Ntiamoah, Anjanie Takeyama, Bibianna M Purgina, Paula A Rodriguez-Urrego, Zlatko Marusic, Antonia Jakovcevic, Deborah J Chute, Lara A Dunn, Ian Ganly, Marc A Cohen, David G Pfister, Ronald A Ghossein, Marina K Baine, Natasha Rekhtman, Snjezana Dogan","doi":"10.1016/j.modpat.2024.100674","DOIUrl":"10.1016/j.modpat.2024.100674","url":null,"abstract":"<p><p>The diagnosis and treatment of sinonasal small round epithelial/neuroepithelial malignancies depend on the expression of conventional neuroendocrine markers (NEMs), such as synaptophysin, chromogranin A, INSM1, and CD56/NCAM1. However, these tumors remain diagnostically challenging because of overlapping histologic and immunohistochemical features. The transcriptional regulators ASCL1, NEUROD1, POU2F3, and YAP1 are novel NEM (nNEM) used for the subtyping of small-cell lung cancer (SCLC). Here, we assessed the immunoexpression of nNEM in 76 sinonasal malignancies, including 27 olfactory neuroblastomas (ONB), 14 small-cell neuroendocrine carcinomas (SCNEC), 2 large-cell neuroendocrine carcinomas, 12 sinonasal undifferentiated carcinomas (SNUC), 7 olfactory carcinomas (OC), 11 SWI/SNF-deficient carcinomas, and 3 neuroendocrine tumors. We correlated nNEM expression with the extent of neuroendocrine (NE) differentiation, as defined by averaged conventional NEM expression (NE-high: H-score, ≥150; NE-low: H-score, <150). Dominant NE subtypes were defined by the nNEM with the highest H-score. Coexpression of 2 nNEM with <100 H-score difference defined a codominant NE subtype. NE differentiation positively correlated with NEUROD1 and negatively with YAP1 expression (P < .0001). ONB were NE-high (96%), and all were NEUROD1-dominant/POU2F3-negative/ASCL1-negative (low)/YAP1-negative (low). In contrast to ONB, all OC were NE-low, mostly (71%) codominant subtypes, NEUROD1-low (negative) (100%, P = .0001), and YAP1 high (71%; P = .0001). Most notably, all SNUC were POU2F3-(co)dominant/NEUROD1-negative irrespective of the IDH2 mutations. Sinonasal tumors with high POU2F3 expression showed enrichment for \"tuft cell carcinoma\" and tuft cell signatures (P = .009). Similar to SCLC, SCNEC was heterogeneous in terms of nNEM expression comprising several molecular subtypes, including ASCL1-(co)dominant (43%) cases. All SWI/SNF-deficient carcinomas were consistently ASCL1/NEUROD1/POU2F3-negative and YAP1-positive. ASCL1/NEUROD1/POU2F3/YAP1 are useful markers in the differential diagnosis of ONB, SNUC, OC, and SWI/SNF-deficient carcinomas. Subsets of SNUC and large-cell neuroendocrine carcinomas may represent tuft cell-like carcinomas, suggesting that the tuft cell could be explored as the cell of origin for these tumors. The therapeutic vulnerabilities associated with POU2F3 expression in SCLC suggest that a similar approach might be considered for POU2F3-positive carcinomas of the sinonasal tract. Given their diagnostic and possible therapeutic relevance, nNEM have the potential to transform the way we approach the diagnosis and management of sinonasal small round epithelial/neuroepithelial malignancies.</p>","PeriodicalId":18706,"journal":{"name":"Modern Pathology","volume":" ","pages":"100674"},"PeriodicalIF":7.1,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142755395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}